Breaking News

Breakthrough Breast Cancer Treatment Launched

May 25, 2021 • 7:19 am CDT
(Vax Before Cancer)

Zydus Cadila announced on May 24, 2021, it launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name ‘Ujvira’.

HER2-positive Breast Cancer is considered an aggressive form and constitutes 20 to 25% of all breast cancer cases.

In a step that can significantly reduce treatment cost by almost 80%, the drug is being offered at Rs. 32495 for a 100 mg vial. The current MRP of the existing Trastuzumab Emtansine drug is Rs. 1,59,225 for a 100 mg vial.

Ujvira will be available in two strengths, 100 mg, and 160 mg.

Speaking on this milestone, Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited stated in a press release, “The launch of Ujvira reinforces the innovation capabilities that India has to be able to create complex therapies like ADCs and Zydus' ongoing commitment to offer breakthroughs backed by science and innovation."

"This research breakthrough enables access to a critical drug for patients who are undergoing therapy for breast cancer. We hope that with this innovation, patients will be able to adhere to the treatment and stand to benefit from the advanced technology without worrying about the cost of the treatment.”

Trastuzumab Emtansine ADC biosimilar is a developmental breakthrough due to its complexity in manufacturing and similarity assays. This drug is made by combining Trastuzumab and the cytotoxic compound Emtansine with the help of a stable linker by a process called Antibody Drug Conjugation.

Due to this technology, the targeted delivery of the cytotoxic agent is enabled and the other toxicities on the body are reduced.

Patients already treated with Trastuzumab may still have the disease and would require this therapy as the next step. The high cost of therapy is a barrier to availing this therapy and Ujvira bridges this need, said the company.

Based in India, Zydus Cadila is an innovation-driven, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics, and vaccines. The company employs nearly 25,000 people worldwide, including 1,400 scientists engaged in R & D.

Share